Ruxotor cream is a prescription medicine used to treat mild to moderate atopic dermatitis (eczema) and non-segmental vitiligo in patients 12 years of age and older. It helps reduce inflammation, redness, and itching of the skin.
Ruxolitinib is a Janus kinase (JAK) inhibitor. It works by targeting and inhibiting specific enzymes (JAK1 and JAK2) involved in the inflammatory pathway, which helps control immune overactivity in skin diseases like eczema and vitiligo.
Ruxotor Cream is a generic version of OPZELURA which is Ruxolitinib Phosphate.
No. Ruxolitinib cream is a non-steroidal treatment. It is a targeted topical immunomodulator that reduces inflammation without the long-term skin-thinning effects commonly associated with corticosteroids.
Apply a thin layer of Ruxolitinib cream to the affected areas of skin twice daily, as prescribed by your healthcare provider. Do not use it on more than 10% of your body surface area unless directed by your doctor.
Yes, Ruxolitinib cream can be used on the face and other sensitive skin areas, but only under medical supervision. Avoid contact with eyes, mouth, and mucous membranes.
Treatment duration depends on the condition being treated and how well the cream works for you. For vitiligo, visible improvement may take 24 weeks or more. Always follow your doctor’s guidance and do not stop or continue use without medical advice.
Yes, but inform your doctor about all skin products you are using. Avoid combining it with other topical JAK inhibitors or strong steroids without guidance, as interactions may occur.
Common side effects include application site burning, itching, redness, and acne. Rare but serious effects may include infections, increased risk of skin cancer, or blood clots. Inform your healthcare provider of any unusual symptoms.
It is approved for use in patients aged 12 years and older. Safety and effectiveness in children under 12 have not been established unless prescribed off-label by a specialist.
As a product from Bangladesh, a country under WTO’s TRIPS waiver until 2033, this generic formulation can be manufactured and sold without paying patent royalties, making it more affordable for global patients.
